GLP-1 and Extra-islet Effects
The DOI matches its Crossref record.
Abstract
The main target of action of glucagon-like peptide-1 (GLP-1) is the islet, where the hormone stimulates insulin secretion, promotes beta cell proliferation and neogenesis, and inhibits glucagon secretion. However, GLP-1 receptors are also expressed outside the islets, increasing the likelihood that GLP-1 also plays a role in other organs. These functions are mainly the inhibition of gastric emptying, gastric acid secretion and exocrine pancreatic secretion, indicating that the hormone acts as an enterogastrone--a hormone released from the distal portion of the small intestine that inhibits proximal gastrointestinal events. Another important action of GLP-1 is to induce satiety. Other effects of the hormone include cardioprotection, neuroprotection, induction of learning and memory, stimulation of afferent, sensory nerves, stimulation of surfactant production in the lung, dilatation of pulmonary vessels, induction of diuresis, and also under some conditions, induction of antidiabetic actions unrelated to islet function. Thus, GLP-1 clearly has several manifestations of activity. The physiological relevance of these actions and their contribution to the overall antidiabetic action of GLP-1 when used in treatment of type 2 diabetes remains to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Gut sensing of potassium intake and its role in potassium homeostasis
Youn, J. H. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.04.005 · Cited by 63
“GLP-1 has been shown to have effects on renal sodium excretion and urinary flow (32, 33), and the GLP-1 receptor is expressed in glomerulus and proximal convoluted tubule cells (33).”
BackgroundGut sensing of dietary K+ intake increases renal K+ excretion
Oh, K.-S., Oh, Y. T., Kim, S.-W., Kita, T., Kang, I., & Youn, J. H. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00095.2011 · Cited by 55
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
“demonstrated similar effects that were not suppressed by reserpine, propranolol, or phentolamine, thereby suggesting a direct mode of action [32-34].”
Background
Metadata
- Authors
- Ahrén, B.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-11
- Volume
- 36
- Issue
- 11/12
- Pages
- 842-845
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2032524589
- Cited by
- 68
- References
- 0
- FWCI
- 2.10
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 and Extra-islet Effects. https://app.cochat.ai/papers/10.1055/s-2004-826173
- The paper
- Ahrén, B. (2004). GLP-1 and Extra-islet Effects. Hormone and Metabolic Research. https://doi.org/10.1055/s-2004-826173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.